In our study, a marked accumulation of the colocalization of bound/free GTP with small GTPases Arl8b and Rab7 in both genotypes suggests a lack of endolysosomal mobilization in old age neurons
For currently approved GLP-1 receptor agonists available for weight management in the UK, NICE has established specific eligibility criteria: Semaglutide (Wegovy) NICE TA875 recommends semaglutide for adults with: A body mass index (BMI) of 35 kg/m or above with at least one weight-related comorbidity (such as hypertension, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease), or A BMI of 3034.9 kg/m with at least one weight-related comorbidity, prescribed only in specialist weight management services Evidence of previous unsuccessful weight loss attempts through diet, physical activity, and behavioural interventions Treatment is limited to a maximum of 2 years Liraglutide (Saxenda) NICE TA664 recommends liraglutide for adults with: A BMI of 35 kg/m or above (with or without comorbidities), or A BMI of 3034.9 kg/m with at least one weight-related comorbidity Evidence of previous unsuccessful weight loss attempts Treatment is limited to a maximum of 2 years Both medications must be prescribed as part of a specialist weight management service providing multidisciplinary support, including dietary advice, physical activity programmes, and behavioural interventions
Considerations Oral semaglutide must be taken on an empty stomach with water (absorption issues)
While the GLP-1 group had a higher average BMI and worse asthma control before starting the GLP-1 drugs, they had significant improvements in their asthma scores after being on the GLP-1 medication for a year
SUGAR-FREE RASPBERRY DELIGHT: Say goodbye to hard-to-swallow pills and enjoy a truly delicious sugar-free treat
Oxidative stress, characterized by an overproduction of reactive oxygen species (ROS), disrupts the balance of glutathione within liver cells, leading to glutathione deficiencya common feature in these liver conditions
